180 related articles for article (PubMed ID: 32901821)
1. Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications.
Chatterjee P; Gheblawi M; Wang K; Vu J; Kondaiah P; Oudit GY
Clin Sci (Lond); 2020 Sep; 134(17):2319-2336. PubMed ID: 32901821
[TBL] [Abstract][Full Text] [Related]
2. Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges.
Kazemi-Bajestani SM; Patel VB; Wang W; Oudit GY
Cardiol Res Pract; 2012; 2012():823193. PubMed ID: 22655211
[TBL] [Abstract][Full Text] [Related]
3. Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs.
Wang W; Shen M; Fischer C; Basu R; Hazra S; Couvineau P; Paul M; Wang F; Toth S; Mix DS; Poglitsch M; Gerard NP; Bouvier M; Vederas JC; Penninger JM; Kassiri Z; Oudit GY
Proc Natl Acad Sci U S A; 2019 Jun; 116(26):13006-13015. PubMed ID: 31189595
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-Converting Enzyme 2 Metabolizes and Partially Inactivates Pyr-Apelin-13 and Apelin-17: Physiological Effects in the Cardiovascular System.
Wang W; McKinnie SM; Farhan M; Paul M; McDonald T; McLean B; Llorens-Cortes C; Hazra S; Murray AG; Vederas JC; Oudit GY
Hypertension; 2016 Aug; 68(2):365-77. PubMed ID: 27217402
[TBL] [Abstract][Full Text] [Related]
5. [The functional role of endogenous APJ agonists; Apelin and Elabela/Toddler in cardiovascular diseases].
Sato T; Kuba K
Nihon Yakurigaku Zasshi; 2019; 153(4):172-178. PubMed ID: 30971657
[TBL] [Abstract][Full Text] [Related]
6. Apelin is a positive regulator of ACE2 in failing hearts.
Sato T; Suzuki T; Watanabe H; Kadowaki A; Fukamizu A; Liu PP; Kimura A; Ito H; Penninger JM; Imai Y; Kuba K
J Clin Invest; 2013 Dec; 123(12):5203-11. PubMed ID: 24177423
[TBL] [Abstract][Full Text] [Related]
7. Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists.
de Oliveira AA; Vergara A; Wang X; Vederas JC; Oudit GY
Peptides; 2022 Jan; 147():170697. PubMed ID: 34801627
[TBL] [Abstract][Full Text] [Related]
8. The ACE2/Apelin Signaling, MicroRNAs, and Hypertension.
Chen LJ; Xu R; Yu HM; Chang Q; Zhong JC
Int J Hypertens; 2015; 2015():896861. PubMed ID: 25815211
[TBL] [Abstract][Full Text] [Related]
9. Uremic Apelin and Leucocytic Angiotensin-Converting Enzyme 2 in CKD Patients.
Trojanowicz B; Ulrich C; Girndt M
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33255902
[TBL] [Abstract][Full Text] [Related]
10. The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases.
Qaradakhi T; Gadanec LK; McSweeney KR; Tacey A; Apostolopoulos V; Levinger I; Rimarova K; Egom EE; Rodrigo L; Kruzliak P; Kubatka P; Zulli A
Clin Exp Pharmacol Physiol; 2020 May; 47(5):751-758. PubMed ID: 31901211
[TBL] [Abstract][Full Text] [Related]
11. Brain angiotensin converting enzyme-2 in central cardiovascular regulation.
Mohammed M; Berdasco C; Lazartigues E
Clin Sci (Lond); 2020 Oct; 134(19):2535-2547. PubMed ID: 33016313
[TBL] [Abstract][Full Text] [Related]
12. The role of ACE2 in cardiovascular physiology.
Oudit GY; Crackower MA; Backx PH; Penninger JM
Trends Cardiovasc Med; 2003 Apr; 13(3):93-101. PubMed ID: 12691672
[TBL] [Abstract][Full Text] [Related]
13. Apelin and ACE2 in cardiovascular disease.
Kalea AZ; Batlle D
Curr Opin Investig Drugs; 2010 Mar; 11(3):273-82. PubMed ID: 20178040
[TBL] [Abstract][Full Text] [Related]
14. ACE2 and the Homolog Collectrin in the Modulation of Nitric Oxide and Oxidative Stress in Blood Pressure Homeostasis and Vascular Injury.
Yang G; Chu PL; Rump LC; Le TH; Stegbauer J
Antioxid Redox Signal; 2017 Apr; 26(12):645-659. PubMed ID: 27889958
[TBL] [Abstract][Full Text] [Related]
15. The Metalloprotease Neprilysin Degrades and Inactivates Apelin Peptides.
McKinnie SM; Fischer C; Tran KM; Wang W; Mosquera F; Oudit GY; Vederas JC
Chembiochem; 2016 Aug; 17(16):1495-8. PubMed ID: 27377680
[TBL] [Abstract][Full Text] [Related]
16. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
Li XC; Zhang J; Zhuo JL
Pharmacol Res; 2017 Nov; 125(Pt A):21-38. PubMed ID: 28619367
[TBL] [Abstract][Full Text] [Related]
17. ACE2: a new target for cardiovascular disease therapeutics.
Raizada MK; Ferreira AJ
J Cardiovasc Pharmacol; 2007 Aug; 50(2):112-9. PubMed ID: 17703127
[TBL] [Abstract][Full Text] [Related]
18. Kallikrein-kinin system as the dominant mechanism to counteract hyperactive renin-angiotensin system.
Regoli D; Gobeil F
Can J Physiol Pharmacol; 2017 Oct; 95(10):1117-1124. PubMed ID: 28384411
[TBL] [Abstract][Full Text] [Related]
19. Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure.
Patel VB; Zhong JC; Grant MB; Oudit GY
Circ Res; 2016 Apr; 118(8):1313-26. PubMed ID: 27081112
[TBL] [Abstract][Full Text] [Related]
20. ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.
Mendoza-Torres E; Oyarzún A; Mondaca-Ruff D; Azocar A; Castro PF; Jalil JE; Chiong M; Lavandero S; Ocaranza MP
Ther Adv Cardiovasc Dis; 2015 Aug; 9(4):217-37. PubMed ID: 26275770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
